重组人IL-11治疗对放化疗鼻咽癌患者预后的影响

Effect of recombinant human interleukin-11 treatment on prognosis of patients with radiochemoradiotherapy in the treatment of nasopharyngeal carcinoma

目的:探讨重组人IL-11治疗对放化疗鼻咽癌患者预后的影响。方法:将78例鼻咽癌患者按随机信封抽签原则分为观察组与对照组各39例,对照组给予常规放化疗,观察组在对照组治疗的基础上给予重组人IL-11治疗,两组都完成2个周期治疗。结果:观察组总有效率(87.2%)高于对照组(59.0%),差异有统计学意义(P<0.05)。观察组在治疗期间放射性口腔黏膜炎0级14例,Ⅰ级6例,Ⅱ级14例,Ⅲ级5例;对照组0级28例,Ⅰ级5例,Ⅱ级4例,Ⅲ级2例,总体比较差异有统计学意义(P<0.05)。治疗后观察组与对照组的血清CRP分别为(5.32±1.92)mg/L和(12.44±2.48)mg/L,明显低于治疗前的(24.59±3.14)mg/L和(24.12±2.87)mg/L(均P<0.05);治疗后,观察组血清CRP明显低于对照组(P<0.05)。治疗后观察组与对照组的疼痛评分明显低于治疗前(P<0.05);治疗后,观察组疼痛评分低于对照组(P<0.05)。结论:重组人IL-11治疗在放化疗鼻咽癌患者中的应用能促进血清CRP表达下降,缓解疼痛,减轻放射性口腔黏膜炎,从而提高预后疗效。

Objective： To investigate the effects of recombinant human IL 11 treatment on prognosis of pa tients with radiochemoradiotherapy in the treatment of nasopharyngeal carcinoma. Method： Seventy-eight cases of nasopharyngeal carcinoma patients were selected as the research object, all the patients were equally divided into observation group and control group with 39 cases in each group accorded to the random draw envelope principle. The control group received conventional ehemoradiotherapy treatment, the observation group received the Ig-11 treatment based on the treatment in control group, the treatment cycles in the two groups were 2 cycles. Result= After treatment, the total effective rates of the observation group and the control group were 87.2% and 59.0%, respectively, the total effective rate of the observation group was significantly higher than that of the control group （P〈0.05）. There were 14 cases of grade 0 radiation-induced oral mucositis, 6 cases of grade Ⅰ , 14 cases of grade Ⅱ , 5 cases of grade Ⅲ in the observation group during the treatment; There were 28 cases of grade 0 radia- tion-induced oral mucositis, 5 cases of grade Ⅰ , 4 cases of grade Ⅱ , 2 cases of grade Ⅲ in the control group dur- ing the treatment there was statistically significant difference between the two groups（P〈0.05）. After treatment, the serum CRP of observation group and control group were（5.32±1.92） mg/L and （12.4±2.48） mg/L that were significantly lower than before treatment of the（24.59±3.14）mg/L and（24.12 ± 2.87）mg/L（ P〈0.05）, se- rum levels of CRP after treatment in the observation group were significantly lower than the control group （P〈 0.05）. After treatment, the pain scores of the observation group and the control group were significantly lower than those before treatment （P〈0.05）, and the pain scores of the observation group after treatment were signifi- cantly lower than the control group （P〈0.05）. Conclusion： The application of recombinant human IL-11 in the treatment of nasopharyngeal carcinom patients with radiochemoradiotherapy can decrease the expression of CRP, reduce the pain, relieve the oral mucositis and improve the prognosis.